Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (Review)

Herbst C, Naumann F, Kruse EB, Monsef I, Bohlius J, Schulz H, Engert A

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1

http://www.thecochranelibrary.com

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**TABLE OF CONTENTS**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEADER</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>PLAIN LANGUAGE SUMMARY</td>
<td>2</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>3</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>4</td>
</tr>
<tr>
<td>METHODS</td>
<td>5</td>
</tr>
<tr>
<td>RESULTS</td>
<td>7</td>
</tr>
<tr>
<td>Figure 1.</td>
<td>8</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>10</td>
</tr>
<tr>
<td>AUTHORS' CONCLUSIONS</td>
<td>11</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>11</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>11</td>
</tr>
<tr>
<td>CHARACTERISTICS OF STUDIES</td>
<td>16</td>
</tr>
<tr>
<td>DATA AND ANALYSES</td>
<td>20</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>20</td>
</tr>
<tr>
<td>HISTORY</td>
<td>27</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF AUTHORS</td>
<td>27</td>
</tr>
<tr>
<td>DECLARATIONS OF INTEREST</td>
<td>27</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>27</td>
</tr>
</tbody>
</table>
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy

Christine Herbst¹, Frauke Naumann², Eva-Brigitta Kruse³, Ina Monsef¹, Julia Bohlius⁴, Holger Schulz¹, Andreas Engert¹

¹Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. ²Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany. ³Beratungszentrum für Hygiene, Freiburg, Germany. ⁴Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Contact address: Christine Herbst, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpen Str. 62, Cologne, 50924, Germany. christine.herbst@uk-koeln.de. (Editorial group: Cochrane Haematological Malignancies Group.)

Cochrane Database of Systematic Reviews, Issue 1, 2009 (Status in this issue: New)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DOI: 10.1002/14651858.CD007107.pub2
This version first published online: 21 January 2009 in Issue 1, 2009.
Last assessed as up-to-date: 2 September 2008. (Help document - Dates and Statuses explained)


ABSTRACT

Background

Febrile neutropenia (FN) and other infectious complications are some of the most serious treatment-related toxicities of chemotherapy for cancer, with a mortality rate of 2% to 21%. The two main types of prophylactic regimens are granulocyte (G-CSF) or granulocyte-macrophage colony stimulating factors (GM-CSF); and antibiotics, frequently quinolones or cotrimoxazole. Important current guidelines recommend the use of colony stimulating factors when the risk of febrile neutropenia is above 20% but they do not mention the use of antibiotics. However, both regimens have been shown to reduce the incidence of infections. Since no systematic review has compared the two regimens, a systematic review was undertaken.

Objectives

To compare the effectiveness of G-CSF or GM-CSF with antibiotics in cancer patients receiving myeloablative chemotherapy with respect to preventing fever, febrile neutropenia, infection, infection-related mortality, early mortality and improving quality of life.

Search strategy

We searched The Cochrane Library, MEDLINE, EMBASE, databases of ongoing trials, and conference proceedings of the American Society of Clinical Oncology and the American Society of Hematology (1980 to 2007). We planned to include both full-text and abstract publications.

Selection criteria

Randomised controlled trials comparing prophylaxis with G-CSF or GM-CSF versus antibiotics in cancer patients of all ages receiving chemotherapy or bone marrow or stem cell transplantation were included for review. Both study arms had to receive identical chemotherapy regimes and other supportive care.

Data collection and analysis
Trial eligibility and quality assessment, data extraction and analysis were done in duplicate. Authors were contacted to obtain missing data.

Main results

We included two eligible randomised controlled trials with 195 patients. Due to differences in the outcomes reported, the trials could not be pooled for meta-analysis. Both trials showed non-significant results favouring antibiotics for the prevention of fever or hospitalisation for febrile neutropenia.

Authors’ conclusions

There is no evidence for or against antibiotics compared to G(M)-CSFs for the prevention of infections in cancer patients.

PLAIN LANGUAGE SUMMARY

Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy

Cancer treatment with chemotherapy (anti-cancer drugs) or bone marrow or stem cell transplantation disrupts the immune system and lowers white blood cell counts. This increases a person's risk of infection. Both granulocyte colony stimulating factors (GFS) and antibiotics can reduce the risk of infection associated with cancer treatments. The review compared the effectiveness of antibiotics to GFSs for the prevention of infection and death. Only two studies were found that compared the two methods of prophylaxis. The studies could not be pooled but both showed a non-significant trend towards a reduction of infection or fever in patients receiving antibiotics. More research is needed to determine the best prophylaxis against infection in cancer patients.
**BACKGROUND**

**Description of the condition**

Febrile neutropenia (FN) and other infectious complications are some of the most serious treatment-related toxicities of chemotherapy for cancer. The risk of febrile neutropenia and subsequent infection is directly related to the duration and severity of neutropenia (Bodey 1966; Bodey 1986). Infectious complications constitute major dose-limiting side effects in patients undergoing myelosuppressive therapy. Special risk circumstances such as patient age greater than 65 years or poor performance status impact on the associated morbidity and mortality (Kuderer 2006; Pizzo 1999). The mortality rate associated with febrile neutropenia in cancer patients is between 2% to 21% (Smith 2006).

FN can be prevented by a prophylactic regimen. Prophylaxis started upfront in the first chemotherapy cycle or in parallel with documented or anticipated neutropenia is called primary prophylaxis, whereas secondary prophylaxis is given to patients who had already experienced episodes of FN in an earlier chemotherapy cycle. Effective prophylaxis using either colony stimulating factors or antibiotics (or both) would decrease clinically relevant negative outcomes such as all cause mortality, infection-related mortality, and infectious complications. Given the high costs of the consequences of FN, and also of the colony stimulating factors themselves, economic arguments are introduced into discussions on the best prophylactic strategy (Kuderer 2006; Leibovici 2006; Tjan-Heijnen 2003).

Another alternative, immunglobulins is not effective in preventing infections in patients with haematological malignancies (Raanani 2008).

In clinical trials addressing the prevention of FN, granulocyte or granulocyte-macrophage colony stimulating factors (G(M)-CSFs) have been reported to be effective in reducing the duration and severity of chemotherapy-induced febrile neutropenia (Johnston 2000; Jones 1996; Holmes 2002). Prophylaxis using antibiotics has also been shown to be beneficial with reduced fever, incidence of infections, and hospitalisations (Bucaneve 2005; Cullen 2005) for example. The prophylactic strategy of combining antibiotics and G-CSF succeeded in reducing the incidence of FN as well (Timmer-Bonte 2005).

**Description of the intervention**

**Colony stimulating factors**

G(M)-CSF predominantly augments the proliferation, maturation, and release of neutrophils, resulting in a dose-dependent increase in circulating neutrophils (Bronchud 1988; Morstyn 1988). G-CSF is a growth factor for the myeloid lineage that stimulates the growth of granulocytes and eosinophil colonies; GM-CSFs also stimulate the growth of macrophages (Griffin 1990). G-CSF and GM-CSF are usually well tolerated with only a moderate number of adverse events. Limited information is available regarding differences in the incidence of adverse events between the two types of colony stimulating factors (Smith 2006). Little information is also available about the comparative efficacy of these two agents (Smith 2006). The prophylactic efficacy of colony stimulating factors is independent of the infectious organism and they are believed to function via the shortening of the neutropenic episode. The current ASCO guidelines (Smith 2006) justify the administration of CSFs in clinical settings where the expected risk of suffering FN is approximately 20%. In addition to the myelotoxicity of the planned chemotherapy regimen, patient-specific risk factors are to be taken into account. Secondary prophylaxis with CSFs is recommended for patients who have developed a neutropenic complication in a previous chemotherapy cycle and in whom a reduced dose might compromise disease-free or overall survival, or treatment outcome. Other guidelines such as the NCCN and the EORTC have similar recommendations (Aapro 2006; Lyman 2005).

Thus far, randomised controlled trials (Crawford 1991; Trillet-Lenoir 1993) and subsequent meta-analyses have shown that primary prophylaxis with CSF is effective, in both patients with solid and haematological malignancies, in reducing FN (Bohlius 2008; Hackshaw 2004; Lyman 2002; Sung 2004; Sung 2007; Wittman 2006). Furthermore, G(M)-CSFs may decrease hospitalisation and the use of intravenous therapeutic antibiotics (Crawford 1991; Trillet-Lenoir 1993). In a meta-analysis on the use of G(M)-CSFs in cancer patients hospitalised with established FN a possible benefit of adding G(M)-CSFs to antibiotic treatment on infection-related mortality and length of hospitalisation was observed (Clark 2005). Recently a meta-analysis by Kuderer 2006 showed that under certain standard dose chemotherapy regimens early and infection-related mortality were also reduced with primary G-CSF prophylaxis. However, none of the meta-analyses with less restrictive inclusion criteria were able to demonstrate that prophylactic administration of G(M)-CSF improved overall survival when compared to placebo or no treatment. None of these analyses addressed the question of G(M)-CSF versus antibiotics, which is a question closer to clinical reality. One analysis did a subgroup analysis of those studies in which the published report mandated antibiotic prophylaxis compared to those that did not and found no difference between the groups (Sung 2007). This may be due to the high number of trials where no information about antibiotic prophylaxis use is available. In addition, this meta-analysis included studies that analysed cycles of chemotherapy as opposed to patients. The distortive effect of such an analysis is difficult to estimate.

Of the many meta-analyses looking at G(M)-CSF versus placebo or no treatment only one meta-analysis, restricted to patients with lymphoma, was published in The Cochrane Library (Bohlius 2008). This analysis found a reduction in the rate of infections (odds ratio (OR) 0.74; 95% CI 0.64 to 0.85) but no effect on infection-related mortality (OR 1.37 favouring control; 95% CI 0.66 to
A number of other meta-analyses have been undertaken by authors funded by pharmaceutical companies that produce G(M)-CSFs; this was information not always disclosed in the text of the meta-analysis but retrieved from other publications by the authors (Hackshaw 2004; Kuderer 2007; Wittman 2006). These meta-analyses tended to show a stronger effect of G(M)-CSF in preventing infections and on infection-related mortality than Bohlius 2008, or reported the results as ORs and not as relative risks (RR). As an example of the former, Bohlius 2008 reported a RR of 1.37 (95% CI 0.66 to 2.82) for the outcome infection-related mortality, from eight trials involving lymphoma patients, as compared with a RR of 0.58 (95% CI 0.28 to 1.23) reported by Kuderer 2007 from five trials (in the subgroup of patients with lymphoma). For an example of the latter, for FN in the paediatric population of Wittman 2006 the OR was 0.59 (recalculated as RR 0.82), which compares to the RR of 0.82 reported by Sung 2007 for the paediatric patient subgroup.

**Antibiotics**

In contrast to the prophylactic use of G(M)-CSFs, the prophylactic use of antibiotics in patients with cancer and neutropenia is more controversial. Several important guidelines are opposed to it (Lyman 2005; Smith 2006). Prophylaxis using antibiotics targets potential pathogens only and, in contrast to colony-stimulating factors, does not deal with the dose-limiting effect of haematological toxicity which is particularly relevant for dose-intensification schemes. A major concern of routine prophylactic use of antibiotics in patients with cancer and neutropenia is that it increases bacterial resistance to these agents. This may, in turn, compromise the success of treating serious infections in current as well as future patients by the spread of (multi)resistance. In addition, hypersensitivity reactions, gastrointestinal toxicities, and the promotion of fungal overgrowth after antibiotics put the patient at risk of potentially serious adverse events. Thus these aspects may limit their efficacy in reducing infection-related morbidity or mortality (Carratala 1995; Gafter-Gvili 2007; Somolinos 1992).

During the last decade, prophylaxis with antibiotics was studied in a number of randomised clinical trials. The evidence provided was not regarded as entirely convincing because none of the studies were sufficiently large to provide conclusive evidence on the real efficacy of prophylaxis (Bucaneye 2005; Cullen 2005; Karp 1987; Lew 1995). Subsequent meta-analyses suggested that prophylaxis using antibiotics reduces the incidence of gram-negative bacterial infection, total infection, fever episodes, and hospitalisation (Cruciani 2003; Engels 1998). Moreover, a recently published meta-analysis of data on antibiotic prophylaxis (or more specifically fluoroquinolones) compared to placebo or no intervention demonstrated that not only infections were reduced but all cause mortality and infection-related mortality were too (Gafter-Gvili 2005; Leibovici 2006). One important question which is still unanswered is whether prophylaxis should be considered for all patients with cancer and neutropenia. In another meta-analysis on antibiotic prophylaxis the majority of patients were suffering from haematological malignancies and received high-dose chemotherapy and bone marrow transplantation, with only a few studies focusing on solid tumours (Cullen 2005; Gafter-Gvili 2005). Another factor possibly compromising the results of the main meta-analysis is that studies were included that randomised chemotherapy cycles and not patients, or reported cycle-based outcomes as opposed to a true incidence (where the number of patients and not cycles are analysed). Again, no information on G(M)-CSFs compared to antibiotics was available from these analyses.

**Why it is important to do this review**

The best prophylactic treatment of FN in cancer patients receiving myeloablative chemotherapy remains controversial and, in general, international guidelines concentrate on either antibiotics or G(M)-CSF. The evidence outlined above suggests that prophylaxis with an antibiotic might be as effective as with G(M)-CSF for reducing both infections and mortality. A prospective randomised trial comparing antibiotics versus G(M)-CSF in stage IV breast cancer patients treated with intermediate-dose chemotherapy showed no difference between both groups, while the cost of G(M)-CSF was almost seven times higher than that of the antibiotics (Schroder 1999). To our knowledge the present Cochrane Review is the first systematic review that compares G(M)-CSFs to antibiotics, even though clinicians are currently faced with the choice of using G(M)-CSFs, antibiotics, or both. Often the mortality rates in clinical trials of prophylactic regimes for FN are too low to allow an accurate assessment of the effect of prophylaxis on important clinical endpoints such as mortality or survival (Elting 2002). In this situation, meta-analyses that analyse much higher numbers of similarly treated patients are a suitable tool to evaluate the overall effect of regimens that showed statistically insignificant results in (underpowered) clinical trials (Pau 2005). During the systematic assessment of available evidence it is very important to account for both clinical and methodological differences in the individual trials, such as the definition of important endpoints and the multitude of different prophylaxis schedules. There may also be considerable heterogeneity introduced by different inclusion and exclusion criteria, or regional differences in pathogen epidemiology or resistance patterns.

**OBJECTIVES**

To identify, critically evaluate, describe, statistically analyse, and summarise the evidence regarding the effectiveness of prophylactic antibiotic treatment compared to prophylactic use of colony stimulating factors in preventing febrile neutropenia (FN), severe infections, infection-related mortality, and overall mortality in cancer patients undergoing myelosuppressive chemotherapy. This includes bone marrow transplantation and stem cell transplantation.
M E T H O D S

Criteria for considering studies for this review

Types of studies
Only randomised controlled trials comparing G(M)-CSF prophylaxis with antibiotic prophylaxis in cancer patients receiving myeloablative chemotherapy were included. Non-randomised and quasi-randomised studies, for example alternate treatment allocation or allocation by date of birth, were excluded as these study designs are regarded to be more prone to bias (Higgins 2006). In addition, trials looking at peri-operative infection prophylaxis, stem cell mobilisation, and priming of malignant cells with G(M)-CSFs were excluded.

Types of participants
We planned to include paediatric and adult, male and female patients with a confirmed diagnosis of any type of cancer who were undergoing myelosuppressive chemotherapy, bone marrow transplantation, or stem cell transplantation. Both solid and haematological malignancies were eligible.

Types of interventions
We reviewed trials comparing G(M)-CSF and antibiotics in the primary prophylaxis of infection-related complications. Trials that examined pegylated G(M)-CSF (pegfilgrastim) were eligible provided pegfilgrastim was given once, 24 hours after the completion of chemotherapy. Trials looking at secondary prophylaxis, defined as prophylaxis in a patient who suffered from FN in an earlier course of chemotherapy, were also eligible but a subgroup analysis was planned. No trials examining secondary prophylaxis were identified. Therapeutic interventions for FN are not part of this review.

We included studies in which the intended chemotherapy regimen did not differ between study arms. Therefore, we excluded studies which compared dose-intensified, dose-accelerated, or dose-dense regimens with standard chemotherapy as this resulted in different chemotherapy protocols in the arm that received antibiotic prophylaxis and the arm that received CSF prophylaxis. Trials with more than two arms were included provided at least two arms with the relevant comparison had the same chemotherapy protocol.

Types of outcome measures

Primary outcomes
- Overall survival
- Microbiologically or clinically, or both, documented infections

Any definition of clinically documented or microbiologically documented infections given by authors was accepted. If available, data on all and not only severe clinically or microbiologically documented infections were extracted. Microbiologically documented infections were required to have some kind of cultural confirmation of the infection. Infections reported without information on microbiological confirmation were considered to be clinically documented infections.

Secondary outcomes
- Severe infections
- Infectious episodes
- Frequency of febrile neutropenia (FN) (any definition of fever and neutropenia accepted)
- Frequency of fever (any definition)
- All cause mortality (including infection-related, treatment-related, or on-trial mortality)
- Quality of life (QoL)

In patient populations with curative treatment intent, overall survival is considered to be the most important clinical endpoint. Studies focusing on the efficacy of prophylaxis only will most likely have only short follow up, mainly providing information on early mortality. Determining the cause of death in severely ill patients can be associated with measurement bias. Therefore, all cause mortality, comprising infection-related as well as treatment-related mortality, was extracted.

In patient populations with palliative treatment intent, quality of life is regarded the most relevant clinical outcome measure and will thus be analysed as secondary endpoint. Only quality of life studies using a validated QoL instrument were eligible. No trial examining quality of life was retrieved.

Search methods for identification of studies

Electronic searches
A systematic and comprehensive search strategy based on the highly sensitive search filter for randomised controlled trials (Dickersin 1994) was conducted (1985 to January 2008). The search covered the Cochrane Central Register of Controlled Trials (CENTRAL) and major medical databases (MEDLINE, EMBASE). Proceedings from relevant conferences (American Society of Clinical Oncology, American Society of Hematology) were searched (2000 to 2007).

The search strategy in Appendix 1 was used to search MEDLINE; for EMBASE see Appendix 2; and for CENTRAL see Appendix 3.

Searching other resources

In addition, we screened references from identified trials, relevant reviews, guidelines, and databases of ongoing clinical trials. No language restriction was applied. In order to avoid publication and reporting bias, abstract publications and unreported data were eligible for the review. Studies that seemed to meet inclusion criteria from their title and abstract were retrieved as full text for further evaluation. It was planned to identify duplicate reports in order to avoid duplication bias. No duplicate report was retrieved.

Data collection and analysis
Study selection

Trials were selected if they met the inclusion criteria as specified above. At every stage of searching and screening the overall number of studies identified, excluded, and included, with the reasons given, were documented in a QUOROM flow diagram (Moher 1999).

Assessment of methodological quality

At the level of the single trials

The quality of eligible studies was independently rigorously evaluated by two review authors. The following quality components, which are part of the CONSORT (Moher 2003) statement, were assessed.

1. Was treatment allocation concealed?
2. Were clinicians and participants blinded to the assigned treatment?
3. Were outcome assessors blinded to the assigned treatment?
4. Were number of withdrawals, drop outs, and losses to follow up in each group stated; and were the numbers less than 10% and equally distributed between arms?
5. Were the participants included in the analyses as part of the groups to which they were allocated (intention-to-treat analysis)?

Full-text versions of eligible studies were used to obtain data. Where these did not provide sufficient information, authors were contacted for further details. Furthermore, trials were classified as high quality trials (allocation concealment, intention-to-treat analysis with less than 10% loss, and a ratio of loss of less than 2:1 between arms) and low quality trials (not fulfilling at least one of the criteria for high quality) for a sensitivity analysis.

Data extraction

Data from the studies were extracted by two review authors (per study) using a standardised data extraction form that contained the following items.

1. General information: author, title, source, publication date, publication type (full text, abstract, unpublished).
2. Study characteristics: trial design, interventions, setting, trial dates, inclusion and exclusion criteria, comparability of groups, treatment allocation, masking, subgroup analysis, statistics, power calculations, length of follow up, study quality, funding source.
3. Participant characteristics: age; diagnosis; stage of disease; prior treatments; number of participants recruited, allocated, and evaluated; participants lost to follow up; noticeable differences in risk factors for developing FN.
4. Interventions: duration; type; dose and timing of G(M)-CSF; antibiotics, and other infection prophylaxis (e.g. antymycotics); concomitant treatment (setting, duration, type of chemotherapy); and supportive care (e.g. type of empirical antibiotic therapy).
5. Outcomes:
   i) primary: overall survival (results of a survival analysis with time included in the analysis), microbiologically or clinically, or both, documented infections;
   ii) secondary: severe infections, infectious episodes, QoL, frequency of FN, frequency of fever, all cause mortality as a binary outcome (including infection-related, treatment-related, and early mortality).

Publications reporting on more than one trial would have been extracted using one data extraction form for each trial. Trials reported on in more than one publication would have been extracted on one form only. Extracted data were checked by a second review author. Data entry into statistical software was done by one author and checked for accuracy by a second author.

During the above steps (study selection, assessment of methodological quality, data extraction) potential disagreements between the review authors were resolved by consensus. If an agreement was not reached, a third review author was asked to give his or her opinion.

Data analysis

For statistical analysis, data were entered into Review Manager 5.0. Additional analyses that were not possible with RevMan were planned to be done in the statistical package SAS 9.12. Since no meta-analysis was possible, no further analyses were done. Should future updates allow a meta analysis, data will be analysed as follows. All effect estimates will be obtained separately for each study and then pooled using the Mantel-Haenszel method. A fixed-effect model will be used to calculate an overall treatment effect in meta-analysis. For all analyses corresponding 95% confidence intervals (CI) will be calculated. Time-to-event data (overall survival) will be calculated as hazard ratios (HR) based on the method introduced by Parmar (Parmar 1998; Tierney 2007). For binary data the relative risk (RR) will be used. Numbers needed to treat to benefit (NNTB) and numbers needed to treat to harm (NNTH) will be calculated for ease of interpretation.

The extent of heterogeneity between trials will be tested using a Chi² statistic with the significance level set at P < 0.10. The I² statistic will be used to quantify possible heterogeneity (I² > 25% moderate heterogeneity, I² > 75% high heterogeneity). Expected causes of heterogeneity will be explored by sensitivity and subgroup analyses. If numbers of included studies allow, a linear regression test for publication bias will be conducted; a P value of less than 0.1 will be considered significant for this test. A funnel plot will be generated for visual inspection (Egger 1997; Lau 2006).

Sensitivity analyses (if possible) will be performed for: the overall quality of the studies (high or low), answers to the quality assessment questions mentioned above, duration of study, publication type, and whether the study was designed to measure overall survival.
Subgroup analyses for the main outcomes, survival and infections

Subgroup analyses will be performed for different types of underlying malignant disease, different baseline risk for febrile neutropenia or infection, study setting (in-patients or out-patients), different type of treatment (for example haematologic stem cell transplantation versus standard chemotherapy), different types of G(M)-CSFs used, age, and according to whether regimens included antimycotic prophylaxis.

Interpretation of data reviewed

Conclusions will be based on the evidence reviewed and discussed thoroughly with the review authors. Results will be updated every two years.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies.

Results of the search

The literature search was designed to find all relevant articles where antibiotics or G(M)-CSFs were used as prophylactic agents. Thus 10,924 abstracts were screened, 473 full texts evaluated briefly, and 44 considered for the review. Only two trials were included in the review. For a QUOROM-diagram see Figure 1.
Figure 1. QUORUM-Diagram

10924 abstracts screened

473 full texts evaluated

44 considered for the review

2 trials included

- 404 only one agent
- 8 treatment of FN
- 5 duplicates
- 12 other

- 36 G(M)-CSF + AB vs. AB alone
- 4 AB + G(M)-CSF vs. G(M)-CSF alone
- 1 chemotherapy differs between arms
- 1 non-randomised comparison
Included studies

Two studies fulfilled the entry criteria of this review. Both of the studies involved adults with solid tumours (small cell lung cancer and breast cancer) and compared prophylaxis for at least six cycles (Schroder 1999; Sculier 2001). A total of 195 patients, 40 from Schroder 1999 and 155 from Sculier 2001, were included in this review. In both studies oral antibiotics were compared to regular subcutaneous injections of G-CSF (Schroder 1999) or GM-CSF (Sculier 2001) without blinding of the study participants. Two different antibiotics were used: a combination of ciprofloxacin and amphotericin B with an anti-fungal agent (Schröder 1999), and cotrimoxazole (Sculier 2001).

The study by Sculier 2001 was a three-arm study comparing standard three-week epirubicin 90mg/m², vindesine 3 mg/m², and ifosfamide 5mg/m² (EVI), given intravenously on day one, with antibiotic prophylaxis in one arm to intensive two-week EVI (same dosages) given every two weeks (intensive two-week EVI) with GM-CSF in one arm and antibiotic support in another arm. Only the two arms with the intensive two-week EVI protocol were included in the review. For the purpose of this review the standard three-week EVI arm with antibiotic prophylaxis was excluded as there was no possible comparison to a study arm that received CSF prophylaxis with the same chemotherapy protocol. Overall survival for up to 1000 days, relative and absolute dose intensity, and adverse events including the incidence of documented infections were reported.

The Schroder 1999 study randomised chemotherapy-naive patients receiving three, three-week courses of intravenous cyclophosphamide (1500 mg/m²), epirubicin (80 mg/m²), and 5-fluouracil (1500 or 1000 mg/m²) given on day one; followed by three cycles of intravenous cyclophosphamide (1500 mg/m²), 5-fluouracil (600 mg/m²) on day one and intravenous methotrexate (1500 mg/m²) on day two.

Sculier 2001 administered cotrimoxazole, 160 mg trimethoprim, and 800 mg sulfamethoxazole three times per day, from day three through to the end of each cycle in the antibiotic group. Schroder 1999 used two prophylactic agents in the antibiotic prophylaxis group, a combination of ciprofloxacin (250 mg twice daily) and amphotericin B (500 mg four times per day) on days three through to day 17 of each cycle. The GM-CSF dosage was 5 µg/kg subcutaneously from day three through to day 13, or until neutrophils reached 1000/mm³, in the Sculier 2001 trial; and 263 µg subcutaneous G-CSF (lenograstim) on days 3 through to day 12 of each cycle in the Schroder 1999 trial.

In the Schroder 1999 study episodes of hospitalisation for FN, as well as their durations, and episodes of grade four leukenopia were reported. Infection-related mortality was reported by both Schroder 1999 and Sculier 2001; overall survival, including on-trial mortality, was reported only by Sculier 2001. The only outcome reported by both studies was infection-related mortality.

Excluded studies

We excluded 36 trials that compared antibiotic and G-CSF prophylaxis to antibiotic prophylaxis alone, from either full-text information or further information obtained from the authors (Ardizzone 1994; Bradstock 2001; Burton 2006; Clarke 1999; Dibenedetto 1995; Faber 2006; Geissler 1997; Gonzalez-Vicent 2004; Greenberg 1996; Gulati 1992; Jones 1996; Heath 2003; Heil 1997; Lee 1998; Little 2002; McQuaker 1997; Michel 2000; Miles 1994; Nemunaitis 1995; Nolan 2007; Ojeda 1999; Ottmann 1995; Patte 2002; Pettengell 1999; Przepiorka 2001; Pui 1997; Schmitz 2004; Spitzer 1994; Stahel 1994; Timmer-Bonte 2005; Trigg 2000; Welte 1996; Witz 1998; Yau 1996; Zinzani 1997). Similarly, we excluded four trials that compared antibiotic prophylaxis plus G(M)-CSF to G(M)-CSF prophylaxis alone (Garcia 2000; Garcia-Saez 2002; Lalami 2004; Maiche 1993). One trial was excluded because the chemotherapy (with either G-CSF prophylaxis or antibiotic prophylaxis) differed in the two arms (Tjan-Heijnen 2003). We also excluded one non-randomised comparison (von Minckwitz 2008).

Risk of bias in included studies

Allocation

Both trials were described as randomised but the randomisation procedure was only reported by Sculier 2001 (minimisation technique). The multi-centre Sculier 2001 study reported central randomisation.

Blinding

There was no blinding in either of the studies due to the use of either an oral antibiotic or subcutaneous injections of G(M)-CSF; no information was given about whether or not the assessors were blind.

Selective reporting

At baseline, the distribution of prognostic factors, such as age and stage of disease, were well balanced in both groups of the two studies; only limited information was given by Schroder 1999. Withdrawals and losses to follow up were stated in the Sculier 2001 study and this study also reported intention-to-treat analysis of the various outcomes. The Schroder 1999 study used a per protocol analysis in the sense that courses of chemotherapy with incorrectly administered study drugs were excluded from the analysis.

Effects of interventions

Primary outcome measures

Overall survival

The Kaplan-Meier curves of all three arms, that is the standard-dose antibiotic prophylaxis arm, the dose-dense antibiotic prophylaxis arm, and the dose-dense GM-CSF arm, were identical for the (maximum) duration of observation of 1000 days reported in the Sculier 2001 trial. This was despite dose intensification not being successful in the dose-dense antibiotic arm (the received
reported the incidence of documented infections, with infections in 17/78 patients receiving GM-CSF and 11/77 patients receiving cotrimoxazole (RR 1.53; 95% CI 0.77 to 3.04 for antibiotics, number needed to treat to benefit (NNTB) 13). This corresponded to a trend towards an increased risk of infection in patients receiving GM-CSF. A clear definition of documented infections was not given in the full-text publication of the trial.

**Secondary outcome measures**

**Incidence of severe infections**

Sculier 2001 reported the number of grade III and IV infectious episodes (classification system not mentioned) but not the incidence of infections.

**Infectious episodes**

Sculier 2001 described the total number of infectious episodes as 64/360 cycles (18%) in the GM-CSF group and 41/334 cycles (12%) in the cotrimoxazole group. An OR with CIs was not calculated because the cycles were linked observations.

**Quality of life (QoL)**

Not reported.

**Incidence of febrile neutropenia (FN)**

Schröder 1999 reported hospitalisations for FN in 7/18 patients receiving G-CSF and in 7/22 patients receiving ciprofloxacin and amphotericin B (RR 1.22; 95% CI 0.53 to 2.84 for antibiotics, NNTB 14). This corresponded to a trend towards an increased risk of febrile leukopenia in the group receiving G-CSF. Similar results yet slightly more in favour of ciprofloxacin and amphotericin B were reported for the analysis of courses of chemotherapy with febrile leukopenia.

**Incidence or episodes of fever**

Not reported.

**Infection-related mortality**

Infection-related mortality was the same in both groups of the Schröder 1999 trial: no patient died of infectious causes during the 18-week duration of the trial. In the Sculier 2001 trial infection-related mortality was similar between the two groups with 3/78 infection-related deaths observed in the GM-CSF group compared to 3/77 deaths in the cotrimoxazole group (OR 0.99; 95% CI 0.21 to 4.74).

**Treatment-related or early mortality**

The 100-day mortality was similar in both groups in the Sculier 2001 trial with 7/78 deaths in the GM-CSF group compared to 5/77 deaths in the dose-dense antibiotic group (OR 1.38; 95% CI 0.46 to 4.17 for antibiotics, NNTB 40). This included both early deaths due to cancer and infection-related deaths. Due to the differences in the outcomes reported (incidence of documented infections versus episodes of FN) and the lack of infectious deaths in the Schröder 1999 trial no meta-analysis of the results was attempted. Note, however, that both trials reported similar but not statistically significant reductions of either infections or FN in the antibiotic arm of the study.

**Discussion**

**Summary of main results**

The striking finding of this review is that there are very few studies comparing antibiotics to granulocyte (and macrophage) colony stimulating factors (G(M)-CSF) for infection prophylaxis in cancer patients receiving myelosuppressive chemotherapy or stem cell transplantation.

**Overall completeness and applicability of evidence**

Two trials were identified. Both were in patients with solid cancer and both demonstrated a trend towards a smaller number of infections in the group receiving antibiotics. However, in one of the two trials the chemotherapy dose intensity received by the antibiotic comparison group was much lower than in the GM-CSF group (Sculier 2001), which may explain the increased incidence of infections in the latter group. The lower dose intensity did not negatively affect overall survival.

**Agreements and disagreements with other studies or reviews**

The latest and most comprehensive meta-analysis of G(M)-CSF versus control (Sung 2007) includes over 80 trials with more than 12,000 patients for the outcome all cause mortality. Similarly the most comprehensive antibiotics versus control meta-analysis (Gafter-Gvili 2005) includes 49 trials with more than 6000 patients (for the outcome all cause mortality). The low number of trials directly comparing antibiotics to G(M)-CSFs is surprising considering the higher cost of G(M)-CSFs compared to standard antibiotics. However, a high number of trials comparing G(M)-CSFs to control received funding from pharmaceutical companies that produce G(M)-CSFs. In both of the trials included in this review there was a trend towards the reduction of infections or febrile leukopenia in patients receiving antibiotic prophylaxis, and not G(M)-CSFs. Clearly more trials with larger numbers of patients are required to answer this question, in particular with regard to early infection-related mortality.

Limited data also exists from a non-randomised comparison within a randomised controlled trial by von Minckwitz 2008. In the randomised controlled trial reported by von Minckwitz 2008 the supportive care in this breast cancer study changed over time. This study was based primarily on the chemotherapy regimen of doxorubicin and cyclophosphamide (TAC) and, depending on the initial response rate, patients were randomised to different numbers of cycles of TAC or to TAC compared to vinorelbine and capecitabine (NX). In patients receiving TAC, the
incidence of febrile leukopenia was similar in patients receiving cotrimoxazole alone and daily injections of G-CSF, while patients receiving pegfilgrastim alone or pegfilgrastim and antibiotics had fewer episodes of FN. Interestingly this analysis was sponsored by a pharmaceutical company producing pegfilgrastim and only the TAC arm, and not patients receiving NX, were analysed; which makes publication bias with regard to the chemotherapy arms a possibility. In addition, missing data led to the exclusion of one third of the patients, again possibly compromising the results. While a recent meta-analysis showed that pegfilgrastim is superior to filgrastim (Pinto 2007), no randomised information is available for pegfilgrastim versus antibiotics.

Looking at this limited evidence, the recent recommendations of the ASCO and EORTC guidelines (Aapro 2006; Smith 2006) where antibiotic prophylaxis (not even with or without G(M)-CSF prophylaxis) is not mentioned are surprising. An argument against antibiotic prophylaxis is the occurrence of resistant strains of bacteria. However, this argument is only valid if the G(M)-CSFs are not (much) worse than antibiotics in the first place - a point yet to be proven. The summary estimates of the reduction of infections (or fever, which is less prone to masking of bacterial infection through the prophylaxis used) is higher in the systematic review of antibiotics versus control than the systematic review for G(M)-CSFs versus control. Such an indirect comparison requires a careful analysis of the supportive care used, the patient populations, and study designs of the included trials. This work is underway and will be published outside The Cochrane Library.

AUTHORS’ CONCLUSIONS

Implications for practice

Both antibiotics and granulocyte (and macrophage) colony-stimulating factors are successful in reducing infections in cancer patients receiving myeloablative chemotherapy; see other meta-analyses (for example Gafter-Gvili 2005; Sung 2007). However, as examined here there is insufficient direct evidence from randomised controlled trials to recommend one over the other.

Implications for research

Large, high quality trials comparing antibiotic prophylaxis to infection prophylaxis using G(M)-CSFs are necessary in a wide range of cancer patients.

ACKNOWLEDGEMENTS

The authors wish to thank Olaf Weingart and Nicole Skoetz of the Cochrane Haematological Malignancies Group (CHMG) Editorial Base as well as the Content Editor and theStatistic Editor for commenting on this review. We also thank the Copy-Editor Janet Wale.

REFERENCES

References to studies included in this review

Schroder 1999 [published data only]

Sculier 2001 [published data only]

References to studies excluded from this review

Ardizzoni 1994 [published data only]

Bradstock 2001 [published data only]

Burton 2006 [published data only]

Clarke 1999 [published data only]

Dibenedetto 1995 [published data only]
Dibenedetto SP, Ragus R, Ippolito AM, Lo NL, Di Cataldo A, D’Amico S, et al. Assessment of the value of treatment with granulo-

Faber 2006 (published data only)

Garcia 2000 (published data only)

Garcia-Saenz 2002 (published data only)

Geissler 1997 (published data only)

Gonzalez-Vicent 2004 (published data only)

Greenberg 1996 (published data only)

Gulati 1992 (published data only)

Heath 2003 (published data only)

Heil 1997 (published data only)

Jones 1996 (published data only)

Lalami 2004 (published data only)

Lee 1998 (published data only)

Little 2002 (published data only)

Maiche 1993 (published data only)

McQuaker 1997 (published data only)

Michel 2000 (published data only)

Miles 1994 (published data only)

Nemunaitis 1995 (published data only)

Nolan 2007 (published data only)
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Ojeda 1999  (published data only)

Ottmann 1995  (published data only)

Patte 2002  (published data only)

Pettengell 1992  (published data only)

Piccirillo 1999  (published data only)

Prezpiorka 2001  (published data only)

Pui 1997  (published data only)

Schmitz 2004  (published data only)

Spitzer 1994  (published data only)

Stahel 1994  (published data only)

Timmer-Bonte 2005  (published data only)

Tjan-Heijnen 2003  (published data only)

Trigg 2000  (published data only)

Welte 1996  (published data only)

Witz 1998  (published data only)

Yau 1996  (published data only)

Zinzani 1997  (published data only)

Additional references

Aapro 2006

Bodey 1966
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kuderer 2007

Lau 2006

Leibovici 2006

Lew 1995

Lyman 2005

Lyman 2000

Moher 1999
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses: the QUORUM statement. *Quality of reporting of meta-analyses.*

Moher 2003

Morstyn 1998

Parmar 1998

Paul 2005

Pinto 2007

Pizzo 1999

Raanani 2008

Smith 2005

Somolinos 1992

Sung 2004

Sung 2007

Tierney 2007

Timmer-Bonte 2005

Trillet-Lenoir 1993

von Minckwitz 2008

Wittman 2006
Wittman B, Horan J, Lyman GH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-

Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**CHARACTERISTICS OF STUDIES**

Characteristics of included studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Methods</th>
<th>Participants</th>
<th>Interventions</th>
<th>Outcomes</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schroder 1999</td>
<td>Chemotherapy regimen (3 week cycle): cyclophosphamide 1500 mg/m², epirubicin 80 mg/m², F-FU 1000mg/m² on day one of the first six cycle then cyclophosphamide 1500 mg/m², 5-FU 600mg/m² on day one and iv methotrexate 1500mg/m² on day two for additional 3 cycles</td>
<td>40 patients with de novo metastatic breast cancer, age &lt; 65 years</td>
<td>Antibiotic arm: oral ciprofloxacin 2 X 250mg daily + oral amphotericin B 100mg/ml 4 X 5ml daily on days 3 through 17</td>
<td>episodes of hospitalisation for febrile neutropenia, duration of hospitalisation for febrile neutropenia, grade four leucopenia</td>
<td>No blinding (oral versus sc injections)</td>
</tr>
<tr>
<td>Sculier 2001</td>
<td>3 arm study: standard 3 week chemotherapy regimen, intensive 2 week chemotherapy regimen with antibiotic or G-CSF support. Chemotherapy regimen (6 cycles): epirubicin 90mg/m², vindesine 5mg/m², ifosfamide 5mg/m²</td>
<td>Untreated extensive disease small cell lung cancer, age &lt; 75 y, adequate haematological, renal and hepatic function, no recent myocardial infarction or congestive heart failure, performance status (Karnovski &gt;= 60)</td>
<td>Antibiotic arm: trimethoprim 160mg/sulfamethoxale 800mg orally every 12 hours from day 3 of the first course of chemotherapy until the end of the courses. GM-CSF arm: 5µg/kg GM-CSF (Leucomax) from day 3 to 13 of each cycle or until ANC &gt; 1000/µl</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Sculier 2001  (Continued)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Absolute and relative dose intensity, response rate, overall survival, adverse events, incidence of infections and severe infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Notes</td>
<td>Only the intensive chemotherapy regimen included in meta-analysis. No blinding (oral medication versus sc injections)</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Blinding?</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Characteristics of excluded studies  [ordered by study ID]**

<table>
<thead>
<tr>
<th>Study</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ardizzoni 1994</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Bradstock 2001</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Burton 2006</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Clarke 1999</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Dibenedetto 1995</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Faber 2006</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Garcia 2000</td>
<td>Comparison of antibiotics plus G(M)-CSF versus G(M)-CSF alone</td>
</tr>
<tr>
<td>Garcia-Saenz 2002</td>
<td>Comparison of antibiotics plus G(M)-CSF versus G(M)-CSF alone</td>
</tr>
<tr>
<td>Geissler 1997</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Gonzalez-Vicent 2004</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Greenberg 1996</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Gulati 1992</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Heath 2003</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Study</td>
<td>Comparison Details</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>Heil 1997</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Jones 1996</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Lalami 2004</td>
<td>Comparison of antibiotics plus G-CSF versus G-CSF alone</td>
</tr>
<tr>
<td>Lee 1998</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Little 2002</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Maiche 1993</td>
<td>Comparison of antibiotics plus G-CSF versus G-CSF alone</td>
</tr>
<tr>
<td>McQuaker 1997</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Michel 2000</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Miles 1994</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Nemunaitis 1995</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Nolan 2007</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Ojeda 1999</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Ottmann 1995</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Patte 2002</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Pettengell 1992</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Piccirillo 1999</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Przepiorka 2001</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Pui 1997</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Schmitz 2004</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Spitzer 1994</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Stahel 1994</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Timmer-Bonte 2005</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
</tbody>
</table>
(Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tjan-Heijnen 2003</td>
<td>4-arm study, two with intensive chemotherapy (G-CSF versus G-CSF + antibiotics) and two with standard dose chemotherapy (control versus antibiotics). Excluded due to the differences in the chemotherapy regimens between antibiotics and G-CSF.</td>
</tr>
<tr>
<td>Trigg 2000</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Welte 1996</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Witz 1998</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Yau 1996</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
<tr>
<td>Zinzani 1997</td>
<td>Comparison of G(M)-CSF plus antibiotics versus antibiotics alone</td>
</tr>
</tbody>
</table>
**DATA AND ANALYSES**

This review has no analyses.

**APPENDICES**

**Appendix 1. MEDLINE search strategy**

1. exp ANTI-BACTERIAL AGENTS/
2. (antibacterial$ or anti-bacterial$).tw,kf,ot.
3. antibio$.tw,kf,ot.
4. (antimicrobial$ or anti-microbial$).tw,kf,ot.
5. (anti-mycobacterial$ or antimycobacterial$).tw,kf,ot.
6. bacteriocid$.tw,kf,ot.
7. (selective$ adj3 decontaminat$).tw,kf,ot.
8. ANTIBIOTIC PROPHYLAXIS/
9. exp QUINOLONE/
10. fluoroquinolones$.tw,kf,ot.
11. ciprofloxa#in$.tw,kf,ot.
12. ofloxa#in$.tw,kf,ot.
13. norfloxa#in$.tw,kf,ot.
14. enoxa#in$.tw,kf,ot.
15. pefloxa#in$.tw,kf,ot.
16. exp TRIMETHOPRIM/
17. trimethoprim$.tw,kf,ot.
18. sulfamethoxazol$.tw,kf,ot.
19. trimethoprim-sulfamethoxazol$.tw,kf,ot.
20. tmp-smz$.tw,kf,ot.
21. exp POLYMIXINS/
22. colistin$.tw,kf,ot.
23. (nalidixic$ adj3 acid$).tw,kf,ot.
24. polymyxin$.tw,kf,ot.
25. AMINOLGYCOSIDES/
26. GENTAMICINS/
27. gentami#in$.tw,kf,ot.
28. exp NEBRAMYCIN/
29. tobramy#in$.tw,kf,ot.
30. NEOMYCIN/
31. neomy#in$.tw,kf,ot.
32. VANCOMYCIN/
33. vancomy#in$.tw,kf,ot.
34. ROXITHROMYCIN/
35. roxithromy#in$.tw,kf,ot.
36. RIFAMPIN/
37. (rifampin$ or rifampicin$).tw,kf,ot.
38. BETA-LACTAMS/
39. beta-lactam$.tw,kf,ot.
40. PENICILLINS/
41. peni#illin$.tw,kf,ot.
42. AMOXICILLIN/
43. amoxi#illin$.tw,kf,ot.
44. CEPHALOTHIN/
45. (cephalotin$.tw or cefalotin$.tw).tw,kf,ot.
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
99. ((lung$ or pulmon$) and inflammation$).tw,kf,ot.
100. pneumonit$.tw,kf,ot.
101. engraftment$.tw,kf,ot.
102. (neutrophil$ adj3 recover$).tw,kf,ot.
103. (haematolog$ adj3 recover$).tw,kf,ot.
104. (hematolog$ adj3 recover$).tw,kf,ot.
105. or/79-104
106. exp NEOPLASMS BY HISTOLOGIC TYPE/
107. exp NEOPLASMS BY SITE/
108. neoplas$.tw,kf,ot.
109. tumo?r$.tw,kf,ot.
110. (krebs$ or cancer$).tw,kf,ot.
111. malignan$.tw,kf,ot.
112. (carcino$ or karzino$).tw,kf,ot.
113. karzinom$.tw,kf,ot.
114. sarcom$.tw,kf,ot.
115. leuk#?m$.tw,kf,ot.
116. lymphom$.tw,kf,ot.
117. melano$.tw,kf,ot.
118. metastas$.tw,kf,ot.
119. (mesothelio$ or mesotelio$).tw,kf,ot.
120. carcinomatos$.tw,kf,ot.
121. (gliom$ or glioblastom$).tw,kf,ot.
122. osteo?sarcom$.tw,kf,ot.
123. (blastom$ or neuroblastom$).tw,kf,ot.
124. or/106-123
125. 105 and 124
126. 78 and 125
127. randomized controlled trial.pt.
128. controlled clinical trial.pt.
129. RANDOMIZED CONTROLLED TRIALS/
130. RANDOM ALLOCATION/
131. DOUBLE BLIND METHOD/
132. SINGLE BLIND METHOD/
133. or/127-132
134. (ANIMALS not HUMANS)/
135. 133 not 134
136. clinical trial.pt.
137. exp CLINICAL TRIALS/
139. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
140. PLACEBOS/
141. placebo$.ti,ab.
142. random$.ti,ab.
143. RESEARCH DESIGN/
144. or/136-143
145. 144 not 134
146. 145 not 135
147. COMPARATIVE STUDY/
148. exp EVALUATION STUDIES/
149. FOLLOW UP STUDIES/
150. PROSPECTIVE STUDIES/
151. (control$ or prospectiv$ or volunteer$).ti,ab.
Appendix 2. EMBASE search strategy

1 exp ANTI-BACTERIAL AGENTS/
2 (antibacterial? OR anti-bacterial?).tw.
3 antibio?.tw.
4 (antimicrobial? OR anti-microbial?).tw.
5 (anti-mycobacterial? OR antimycobacterial?).tw.
6 bacteriocid?.tw.
7 (selective ADJ3 decontaminat?).tw.
8 ANTIBIOTIC PROPHYLAXIS/
9 exp QUINOLONE/
10 fluoroquinolones?.tw.
11 ciprofloxa#in?.tw.
12 ofloxa#in?.tw.
13 norfloxa#in?.tw.
14 enoxa#in?.tw.
15 pefloxa#in?.tw.
16 exp TRIMETHOPRIM/
17 trimethoprim?.tw.
18 sulfamethoxazol?.tw.
19 (trimethoprim-sulfamethoxazol? OR (trimethoprim ADJ3 sulfamethoxazol?)).tw.
20 tmp-smz?.tw.
21 exp POLYMYXIN/
22 colistin?.tw.
23 (nalidixic? ADJ3 acid?).tw.
24 polymyxin?.tw.
25 AMINOGLYCOSIDE/
26 GENTAMICIN/
27 gentami#in?.tw.
28 exp NEBRAMYCIN/
29 tobramy#in?.tw.
30 NEOMYCIN/
31 neomy#in?.tw.
32 VANCOMYCIN/
33 vancomy#in?.tw.
34 ROXITHROMYCIN/
35 roxithromy#in?.tw.
36 RIFAMPIN/
37 (rifampin? OR rifampicin?).tw.
38 BETA-LACTAMS/
39 PENICILLINS/
40 AMOXICILLIN/
41 CEPHALOTHIN/
42 CEFTRIAXONE/
43 TICARCILLIN/
44 (beta-lactam? OR beta$ lactam$).tw.
45 peni#illin?.tw.
46 amoxi#illin?.tw.
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. CENTRAL search strategy

#1 MeSH descriptor Anti-Bacterial Agents explode all trees
#2 (antibacterial*) OR (anti-bacterial*)
#3 (antibiotic*)
#4 (antimicrobial*) OR (anti-microbial*) OR (anti-mycobacterial*) OR (antimyocobacterial*) OR (bacteriocid*) OR (selective NEAR/3 decontaminat*)
#5 MeSH descriptor Antibiotic Prophylaxis explode all trees
#6 MeSH descriptor Quinolones explode all trees
#7 (fluoroquinolones) OR (ciprofloxa*in*) OR (ofloxa*in*) OR (norfloxa*in*) OR (enoxa*in*) OR (pafloxa*in*)
#8 MeSH descriptor Trimethoprim explode all trees
#9 (trimethoprim) OR (sulfamethoxazol*) OR (trimethoprim-sulfamethoxazol*, (trimethoprim NEAR/3 sulfamethoxazol*)) OR (tmp-smz*)
#10 MeSH descriptor Polymyxins explode all trees
#11 (colistin) OR (nalidixic NEAR/3 acid) OR (polymyxin)
#12 MeSH descriptor Aminoglycosides explode all trees
#13 MeSH descriptor Gentamicins explode all trees
#14 MeSH descriptor Nebramycin explode all trees
#15 MeSH descriptor Neomycin explode all trees
#16 MeSH descriptor Vancomycin explode all trees
#17 (gentami*in) OR (tobramy*in) OR (meomy*in)
#18 MeSH descriptor Roxithromycin explode all trees
#19 MeSH descriptor Rifampin explode all trees
#20 (vancmy*in) OR (roxithromy*in) OR (rifampin*,rifampicin*)
#21 MeSH descriptor beta-Lactams explode all trees
#22 MeSH descriptor Penicillins explode all trees
#23 MeSH descriptor Amoxicillin explode all trees
#24 MeSH descriptor Cephalothin explode all trees
#25 MeSH descriptor Ceftriaxone explode all trees
#26 MeSH descriptor Ticarcillin explode all trees
#27 (beta-lactam*) OR (peni*illin) OR (amoxi*illin*) OR (cephalot*in*,cefalot*in*) OR (ceftriaxone*)
#28 (tica*illin*) OR (franymycin)
#29 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
#30 MeSH descriptor Colony-Stimulating Factors explode all trees
#31 MeSH descriptor Colony-Stimulating Factors, Recombinant explode all trees
#32 MeSH descriptor Granulocyte Colony Stimulating Factor, Recombinant explode all trees
#33 MeSH descriptor Granulocyte Colony-Stimulating Factor explode all trees
#34 MeSH descriptor Macrophage Colony-Stimulating Factor explode all trees
#35 MeSH descriptor Granulocyte-Macrophage Colony-Stimulating Factor explode all trees
#36 (rhg*csf*,rhgm*csf*) OR (rmethug*,rhmethug*) OR (rhug*,rhugm*) OR (gcsf*,g-csf*) OR (gm-csf*,gmcsf*)
#37 (granulo*yt* NEAR/3 fa*tor*) OR (ma*rophag* NEAR/5 fa*tor*) OR (csf,ti) OR (filgrastim*) OR (neupogen*)
#38 (lenogastrm*) OR (euprotin*) OR (pefg-l-filgras*) OR (neulasta*) OR (leukine)
#39 (molgramastine*) OR (mielogen*) OR (leucomax*) OR (granocyte)
#40 MeSH descriptor Filgrastim explode all trees
#41 (#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40)
#42 MeSH descriptor Leukopenia, this term only
#43 .MeSH descriptor Agranulocytosis explode all trees
#44 (granulocytopen*) OR (agranulocytos*) OR (neutropen*) OR (leu*open*) OR (aplasia, aplastic, aplasion)
#45 (leukocy*t NEAR/5 nadir) OR (neutrophil NEAR/5 nadir)
#46 MeSH descriptor Infection explode all trees
#47 (infect*)
#48 MeSH descriptor Sepsis explode all trees
#49 (septicaemia, septicemia) OR (bacteraem*, bacterem*) OR (fever*) OR (pyrexia) OR (fever NEAR/4 (unknown NEAR/3 origin))
#50 MeSH descriptor Fever explode all trees
#51 MeSH descriptor Fever of Unknown Origin, this term only
#52 (pneumonia) OR (lung inflammation) OR (pulmonary inflammation) OR (pneumonitis)
#53 (#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52)
#54 MeSH descriptor Neoplasms by Histologic Type explode all trees
#55 MeSH descriptor Neoplasms by Site explode all trees
#56 (neoplasm*) OR (krebs,cancer*) OR (malignan*)
#57 (leukaem*,leukem*) OR (lymphom*) OR (melano*) OR (metastas*) OR (mesothelio*,mesotelio*)
#58 (gliom,glioblastom*) OR (osteosarcom*) OR (carcinomatos*) OR (blastom*) OR (neuroblastom*)
#59 MeSH descriptor Pneumonia explode all trees
#60 (#54 OR #55 OR #56 OR #57 OR #58 OR #59)
#61 (#53 OR #59)
#62 (#29 AND #41 AND #61)

HISTORY
Review first published: Issue 1, 2009

CONTRIBUTIONS OF AUTHORS
Christine Herbst: protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis, drafting of final review
Julia Bohlius: protocol development and clinical expertise
Holger Schulz: clinical expertise
Eva Kruse: protocol development
Nauman Frauke: protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis
Ina Monsef: database search
Andreas Engert: clinical expertise and content input

DECLARATIONS OF INTEREST
None
SOURCES OF SUPPORT

Internal sources

- Köln Fortune, Germany.
  Funding programme “Köln Fortune”, Medical Faculty University of Cologne

External sources

- BMBF, Germany.
  The Editorial Base is funded by Federal Ministry of Education and Research (BMBF) No : 01GH0501
- BMBF, Germany.
  Project grant application NO 01KG0612, Federal Ministry of Education and Research (BMBF)